Epigenetic therapy for colorectal cancer

Methods in Molecular Biology

Volumn 1238, Issue , 2015, Pages 771-782

  Vaish, Vivek ^a   Khare, Tripti ^a   Verma, Mukesh ^a   Khare, Sharad ^a  

^a NONE

Author keywords

Acetylation; Colon cancer; Epigenetic therapy; Methylation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BENZAMIDE DERIVATIVE; CYCLINE; DNA METHYLTRANSFERASE INHIBITOR; FATTY ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MG 98; MOCETINOSTAT; NUCLEOSIDE ANALOG; TETRAPEPTIDE; HISTONE;

ARTICLE; CANCER GROWTH; COLORECTAL CANCER; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; HISTONE ACETYLATION; HUMAN; METASTASIS; MRNA EXPRESSION ASSAY; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ACETYLATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; METABOLISM;

ACETYLATION; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS;

EID: 84955343738     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1804-1_40     Document Type: Article

References (101)

1. Migheli F, Migliore L (2012) Epigenetics of colorectal cancer. Clin Genet 8:312–318.
2. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG (2011) Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29:1382–1391.
3. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150:12–27.
4. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33.
5. Roy S, Majumdar AP (2012) Cancer stem cells in colorectal cancer: genetic and epigenetic changes. J. Stem Cell Res. Ther. Suppl 7(6): 10342.
6. You JS, Jones PA (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22:9–20.
7. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463.
8. Nebbioso A, Carafa V, Benedetti R, Altucci L (2012) Trials with ‘epigenetic’ drugs: an update. Mol Oncol 6:657–682.
9. Tost J (2010) DNAmethylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol Biotechnol 44:71–81.
10. Jones PA, Liang G (2009) Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 10:805–811.
11. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird A, Jaenisch R (2000) Non- CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 97:5237–5242.
12. Lister R, Pelizzola M, Dowen RH et al (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462:315–322.
13. Pradhan S, Esteve PO (2003) Mammalian DNA (cytosine-5) methyltransferases and their expression. Clin Immunol 109:6–16.
14. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247–257.
15. Bourc’his D, Xu GL, Lin CS, Bollman B, Bestor TH (2001) Dnmt3L and the establishment of maternal genomic imprints. Science 294:2536–2539.
16. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X (2007) Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 449:248–251.
17. Arita K, Ariyoshi M, Tochio H, Nakamura Y, Shirakawa M (2008) Recognition of hemimethylated DNA by the SRA protein UHRF1 by a base-fl ipping mechanism. Nature 455: 818–821.
18. Bostick M, Kim JK, Estève PO, Clark A, Pradhan S, Jacobsen SE (2007) UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317:1760–1764.
19. Jeong S, Liang G, Sharma S, Lin JC, Choi SH, Han H, Yoo CB, Egger G, Yang AS, Jones PA (2009) Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol 29:5366–5376.
20. Kouzarides T (2007) Chromatin modifi cations and their function. Cell 128:693–705.
21. Schnekenburger M, Diederich M (2012) Epigenetics offer new horizons for colorectal cancer prevention. Curr Colorectal Cancer Rep 8:66–81.
22. Hammoud SS, Cairns BR, Jones DA (2013) Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 25: 177–183.
23. Pogribny IP, Beland FA (2009) DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 66: 2249–2261.
24. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modifi cation maps. Nat Rev Genet 8:286–298.
25. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105:13556–13561.
26. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA (2006) Specifi c activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin modifying drugs in human cancer cells. Cancer Cell 9:435–443.
27. Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, Riggs AD, Pfeifer GP (2008) High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 105: 252–257.
28. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114: 3448–3458.
29. Szyf M (2003) Targeting DNA methylation in cancer. Ageing Res Rev 2:299–328.
30. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253–266.
31. Zhu J, Yao X (2009) Use of DNA methylation for cancer detection: promises and challenges. Int J Biochem Cell Biol 41:147–154.
32. Shah R, Smith P, Purdie C, Quinlan P, Baker L, Aman P, Thompson AM, Crook T (2009) The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br J Cancer 100: 1687–1696.
33. Mayor R, Casadome L, Azuara D, Moreno V, Clark SJ, Capella G, Peinado MA (2009) Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer 100: 1534–1539.
34. deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton- Day C (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55:1337–1346.
35. Szyf M, Pakneshan P, Rabbani SA (2004) DNA methylation and breast cancer. Biochem Pharmacol 68:1187–1197.
36. Szyf M (2005) DNA methylation and demethylation as targets for anticancer therapy. Biochemistry 70:533–549.
37. Esteller M (2003) Relevance of DNA methylation in the management of cancer. Lancet Oncol 4:351–358.
38. Szyf M (2009) Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 49:243–263.
39. Brueckner B, Kuck D, Lyko F (2007) DNA methyltransferase inhibitors for cancer therapy. Cancer J 13:17–22.
40. Goffi n J, Eisenhauer E (2002) DNA methyltransferase inhibitorsstate of the art. Ann Oncol 13:1699–1716.
41. De Abreu R, Lambooy L, Stet E, Vogels- Mentink T, van den Heuvel L (1995) Thiopurine induced disturbance of DNA methylation in human malignant cells. Adv Enzyme Regul 35:251–263.
42. Balch C, Montgomery JS, Paik H-I, Kim S, Huang TH-M, Nephew KP (2005) New anticancer strategies: epigenetic therapies and biomarkers. Front Biosci 10:1887–1931.
43. Esteller M (2006) CpG island methylation and histone modifi cations: biology and clinical signifi cance. Ernst Schering Res Found Workshop 57:115–126.
44. Yoo CB, Cheng JC, Jones PA (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32:910–912.
45. Rao SP, Rechsteiner MP, Berger C, Sigrist JA, Nadal D, Bernasconi M (2007) Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt’s lymphoma Akata cells. Mol Cancer 6:3–8.
46. Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, Redkar S, Jacob, ST (2009) A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 69:4277–4285.
47. Peng X, Pentassuglia L, Sawyer DB (2010) Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern? Circ Res 106:1022–1034.
48. Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M, Lyko F (2005) Epigenetic reactivation of tumor suppressor genes by a novel smallmolecule inhibitor of human DNA methyltransferases. Cancer Res 65:6305–6311.
49. Braun J, Boittiaux I, Tilborg A, Lambert D, Wouters J (2010) The dicyclo-hexyl-amine salt of RG108 (N-phthalyl-ltryptophan), a potential epigenetic modulator. Acta Crystallogr Sect E Struct Rep Online 66:3175–3176.
50. Schirrmacher E, Beck C, Brueckner B, Schmitges F, Siedlecki P, Bartenstein P, Lyko F, Schirrmacher R (2006) Synthesis and in vitro evaluation of biotinylated RG108: a high affi nity compound for studying binding interactions with human DNA methyltransferases. Bioconjug Chem 17:261–266.
51. Suzuki T, Tanaka R, Hamada S, Nakagawa H, Miyata N (2010) Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg Med Chem Lett 20:1124–1127.
52. Amato RJ (2007) Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer 5:422–426.
53. Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G (2008) A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 14:2444–2449.
54. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E (2006) Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 24:159–167.
55. Plummer R, Vidal L, Griffi n M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV (2009) Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 15:3177–3183.
56. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251–260.
57. Ruthenburg AJ, Li H, Patel DJ, Allis CD (2007) Multivalent engagement of chromatin modifi cations by linked binding modules. Nat Rev Mol Cell Biol 8:983–994.
58. Li J, Lin Q, Wang W, Wade P, Wong J (2002) Specifi c targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev 16: 687–692.
59. Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M (1996) HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci U S A 93:14503–14508.
60. De Nadal E, Zapater M, Alepuz PM, Sumoy L, Mas G, Posas F (2004) The MAPK Hog1 recruits Rpd3 histone deacetylase to activate osmoresponsive genes. Nature 427: 370–374.
61. Kim GW, Yang XJ (2011) Comprehensive lysine acetylomes emerging from bacteria to humans. Trends Biochem Sci 36:211–220.
62. Yang XJ, Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9:206–218.
63. Bonfi l C, Walkinshaw DR, Besterman JM, Yang XJ (2008) Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and infl ammatory diseases. Expert Opin Drug Discov 3:1041–1065.
64. Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3:5.
65. Hoshino I, Matsubara H (2010) Recent advances in histone deacetylase targeted cancer therapy. Surg Today 40:809–815.
66. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287–299.
67. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495–528.
68. Archer SY, Meng S, Shei A, Hodin RA (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 95:6791–6796.
69. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27:104–119.
70. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, Troost FJ, Venema K, Brummer RJ (2009) Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28:88–93.
71. Sauer J, Richter KK, Pool-Zobel BL (2007) Physiological concentrations of butyrate favorably modulate genes of oxidative and metabolic stress in primary human colon cells. J Nutr Biochem 18:736–745.
72. Spurling CC, Suhl JA, Boucher N, Nelson CE, Rosenberg DW, Giardina C (2008) The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARbeta2 in colon cancer cells. Nutr Cancer 60:692–702.
73. Lambert DW, Wood IS, Ellis A, Shirazi- Beechey SP (2002) Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer 86:1262–1269.
74. Brim H, Kumar K, Nazarian J, Hathout Y, Jafarian A, Lee E, Green W, Smoot D, Park J, Nouraie M, Ashktorab H (2011) SLC5A8 gene, a transporter of butyrate: a gut fl ora metabolite, is frequently methylated in African American colon adenomas. PLoS One 6:e20216.
75. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG (2007) Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 25:131–138.
76. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC (2001) A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7:3047–3055.
77. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hövelmann S, Göttlicher M, Knuth A, Jäger E (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97:177–182.
78. Lin HY, Chen CS, Lin SP, Weng JR (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397–413.
79. Cang S, Ma Y, Liu D (2009) New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2:22.
80. Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351–1356.
81. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin- binding protein-2, and downregulates thioredoxin. Proc Natl Acad Sci U S A 99:11700–11705.
82. Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schöffski P (2008) Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 26:483–488.
83. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11:459–464.
84. Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011) Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol 6:33.
85. Lee EJ, Lee BB, Kim SJ, Park YD, Park J, Kim DH (2008) Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol 33:767–776.
86. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD (2011) The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res 71:3635–3648.
87. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241: 126–133.
88. Doss H, Jones S, Infante J, Spigel D, Willcutt N, Lamar R, Barton J, Keegan M, Burris HA (2008) A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J Clin Oncol 26(suppl):2567.
89. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, Kwon HK, Hong S, Lee HY, Lee YW, Lee HW (2000) Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60:6068–6074.
90. Rosato RR, Grant S (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30–37.
91. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202.
92. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96:4592–4597.
93. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42:3001–3003.
94. Hurwitz H, Nelson B, O’Dwyer P, Chiorean E, Gabrail N, Li Z, Laille E, Drouin M, Rothenberg ML, Chan E (2008) Phase I/II: the oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. J Clin Oncol 26(suppl):4625.
95. Seow A, Vainio H, Yu MC (2005) Effect of glutathione-S-transferase polymorphisms on the cancer preventive potential of isothiocyanates: an epidemiological perspective. Mutat Res 592:58–67.
96. Higdon JV, Delage B, Williams DE, Dashwood RH (2007) Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 55:224–236.
97. Moy KA, Yuan JM, Chung FL, Wang XL, Van Den Berg D, Wang R, Gao YT, Yu MC (2009) Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms and gastric cancer risk: a prospective study of men in Shanghai. Chin Int J Cancer 125:2652–2659.
98. Ishikawa S, Hayashi H, Kinoshita K, Abe M, Kuroki H, Tokunaga R, Tomiyasu S, Tanaka H, Sugita H, Arita T, Yagi Y, Watanabe M, Hirota M, Baba H (2013) Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer. doi: 10.1002/ ijc.28672 (Ahead of print).
99. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel T, Morreau H, Hommes DW, Peppelenbosch MP, van den Brink GR, Hardwick JC (2011) Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell “stemness” via the bone morphogenetic protein pathway. Gut 60:1544–1553.
100. Huang YW, Kuo CT, Stoner K, Huang TH, Wang LS (2011) An overview of epigenetics and chemoprevention. FEBS Lett 585: 2129–2136.
101. Kim JG, Park MT, Heo K, Yang KM, Yi JM (2013) Epigenetics meets radiation biology as a new approach in cancer treatment. Int J Mol Sci 14:15059–15073